[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-346396-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-346396-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","therapeutic-potential-of-tyrosine-kinase-inhibitors-in-advanced-thyroid-cancer-review-abstract-recent-findings-summary","Therapeutic Potential of Tyrosine Kinase Inhibitors in Advanced Thyroid Cancer - Review - Abstract, Recent Findings, Summary","","Tyrosine kinase inhibitors (TKIs) have become essential for managing advanced thyroid cancers, especially refractory cases unresponsive to conventional treatments. The review highlights therapeutically targetable molecular drivers and oncogenic pathways, including MAPK signaling, and clarifies the role of receptor tyrosine kinases such as VEGFR, PDGFR, and EGFR in disease pathogenesis and progression. It compares multikinase versus selective TKIs, addressing efficacy, toxicity, drug resistance, limited durability, and next-generation combination strategies.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/therapeutic-potential-of-tyrosine-kinase-inhibitors-in-advanced-thyroid-cancer-review-abstract-recent-findings-summary/346396/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/therapeutic-potential-of-tyrosine-kinase-inhibitors-in-advanced-thyroid-cancer-review-abstract-recent-findings-summary/346396.png","ImageObject",300,407,{"name":42,"@type":43},"Patrick","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-29","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",6,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What is the primary purpose of the review on TKIs in advanced thyroid cancer?","Question",{"text":63,"@type":64},"The review explains why tyrosine kinase inhibitors are important for managing advanced thyroid cancers, focusing on molecular drivers and oncogenic pathways that can be therapeutically targeted.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"Which signaling pathways and receptor kinases are emphasized as therapeutic targets?",{"text":68,"@type":64},"The review highlights MAPK signaling and the roles of key receptor tyrosine kinases including VEGFR, PDGFR, and EGFR in tumor pathogenesis and progression.",{"name":70,"@type":61,"acceptedAnswer":71},"What differences are reported between multikinase and selective TKIs?",{"text":72,"@type":64},"Recent studies cited in the review report distinct differences in efficacy, toxicity, and therapeutic use across thyroid cancer subtypes.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},346396,1790923339,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,105,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},"Technology",50,"technology",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},7,"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":127,"language":139,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":12,"update_tm":143,"read_time":144,"preview_page_count":33,"preview_urls":145},549758146520,"https://ap-avatar.wpscdn.com/avatar/80002397d8c0411e94?_k=1775819394049821470","Current Oncology Reports (2026) 28:9  \n[https://doi.org/10.1007/s1](https://doi.org/10.1007/s1) 1912-026-01736-z  \nREVIEW  \nTherapeutic Potential of Tyrosine Kinase Inhibitors in Advanced Thyroid Cancer  \nPrakash Gangadaran1,2 · Vidya Sankarapandian3 · Raksa Arun4 · Kandasamy Nagarajan ArulJothi4 · Ramya Lakshmi Rajendran1,2,5 · Ji Min Oh1,2 · Athesh Kumaraswamy6 · Sridharan Gurunagarajan7 · Byeong-Cheol Ahn1,2,5,8  \nReceived: 10 November 2025 / Accepted: 8 December 2025 © The Author(s) 2026  \nAbstract  \nPurpose of Review Tyrosine kinase inhibitors (TKIs) have become essential agents for managing advanced thyroid cancers, particularly refractory cases that do not respond to conventional therapies. This review emphasizes the key molecular drivers and oncogenic pathways (including the mitogen-activated protein kinase (MAPK) signaling pathway) that are therapeutically targetable, providing the rationale for TKI intervention and unraveling the role of key receptor tyrosine kinases, including VEGFR, PDGFR, and EGFR, in the pathogenesis and progression of thyroid cancer.  \nRecent Findings Recent studies comparing multikinase and selective TKIs show distinct differences in efficacy, toxicity, and therapeutic use across thyroid cancer subtypes. FDA-approved TKIs provide clear clinical benefit, but challenges such as drug resistance, limited response durability, and treatment-related toxicities persist. Emerging next-generation inhibitors, pathway-specific approaches, and combination strategies are being developed to address these limitations.  \nSummary TKI therapy has significantly improved outcomes for patients with advanced thyroid cancers by targeting central molecular pathways that drive tumor growth and survival. While resistance and toxicity continue to restrict optimal longterm benefit, ongoing developments in precision oncology and targeted therapeutics offer promising avenues to refine and enhance TKI-based treatment strategies in the near future.  \nKeywords Tyrosine kinase inhibitors · Thyroid cancer · MAPK signaling pathway · Targeted therapy · Drug resistance  \nRamya Lakshmi Rajendran, Kandasamy NagarajanArulJothi, Raksa Arun, Vidya Sankarapandian and Prakash Prakash contributed equally to this work.  \n􀀍 Byeong-Cheol Ahn [abc2000@knu.ac.kr](abc2000@knu.ac.kr)  \n1 Department of Nuclear Medicine, School of Medicine, Kyungpook National University, 680, Gukchaebosang ro, Jung gu, Daegu 41944, Republic of Korea  \n2 Cardiovascular Research Institute, Kyungpook National University, Daegu 41944, Republic of Korea  \n3 Department of Microbiology and Immunology, Kampala International University, Western Campus, Uganda  \n4 Department of Genetic Engineering, College of Engineering and Technology, SRM Institute of Science and Technology, Potheri, Kattankulathur, Chengalpattu, Tamilnadu, India  \n5 BK21 FOUR KNU Convergence Educational Program of Biomedical Sciences for Creative Future Talents, Department of Biomedical Sciences, School of Medicine, Kyungpook National University, Daegu 41944, Republic of Korea  \n6 School of Sciences, Bharata Mata College (Autonomous), Thrikkakara, Kochi, Kerala Kerala, India  \n7 Department of Biochemistry, SrimadAndavan Arts and Science College (Autonomous), Bharathidasan University, Tiruchirappalli, Tamilnadu 620 005, India  \n8 Department of Nuclear Medicine, Kyungpook National University Hospital, Daegu 41944, Republic of Korea  \n1 3  \nIntroduction  \nThyroid cancer originates from hormone-producing thyroid gland cells, and its incidence has been consistently increasing worldwide [1, 2] . It is classified into four major types, which account for approximately 98% of all thyroid malignancies: differentiated thyroid cancer (DTC), which encompasses both papillary thyroid cancer (PTC) and follicular thyroid cancer (FTC); oncocytic thyroid carcinoma/anaplastic (undifferentiated) thyroid cancer (ATC/UTC); and medullary thyroid cancer (MTC) [3] . PTC is characterized by little colloid, hypercellularity, and enla","cbCaikGElIkoJyk4","https://ap.wps.com/l/cbCaikGElIkoJyk4","pdf",3186977,"English","# Abstract\n## Purpose of Review\n## Recent Findings\n## Summary\n# Introduction","[{\"question\":\"What is the primary purpose of the review on TKIs in advanced thyroid cancer?\",\"answer\":\"The review explains why tyrosine kinase inhibitors are important for managing advanced thyroid cancers, focusing on molecular drivers and oncogenic pathways that can be therapeutically targeted.\"},{\"question\":\"Which signaling pathways and receptor kinases are emphasized as therapeutic targets?\",\"answer\":\"The review highlights MAPK signaling and the roles of key receptor tyrosine kinases including VEGFR, PDGFR, and EGFR in tumor pathogenesis and progression.\"},{\"question\":\"What differences are reported between multikinase and selective TKIs?\",\"answer\":\"Recent studies cited in the review report distinct differences in efficacy, toxicity, and therapeutic use across thyroid cancer subtypes.\"}]","Therapeutic Potential of Tyrosine Kinase Inhibitors in Advanced Thyroid Cancer - Review - Abstract, Recent Findings, Summary | PDF",1790061267,48,[146,150,154,158],{"page_no":22,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/69076737e3cd1dc8147a044d96c51c6d.webp",983,1305,{"page_no":26,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/39b1b9a0da8f9c537ce55ef8c0fbfc1f.webp",982,1304,{"page_no":30,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ad0ab57e460e64d21f49d8fc05a0190e.webp",981,1303,{"page_no":33,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/cbef547cdf84bd3313073625d4f9fdcf.webp",980,1301]